Search for other works by this author on: ...

1University of Minnesota, Minneapolis, MN.

Cancer Biology Evolution Program, Integrated Mathematic Oncology Department, Radiology Department, Moffitt Cancer Center, Tampa, Florida. *Corresponding Author: Robert A. Gatenby, Cancer Biology ...

*Corresponding Author: Anne McTiernan, Public Health Sciences Division, Fred Hutchinson Cancer Center, 1100 Fairview Avenue North, P.O. Box 19024, Seattle, WA 98109. E-mail: [email protected] ...

1Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Freiburg University Medical Center, Freiburg, Germany.

Abstract. Platinum-resistant ovarian cancer remains one of the greatest challenges in oncology, with limited treatment options and poor survival outcomes. To address this unmet need we develop MDC-735 ...

MS Bioworks, LLC, Ann Arbor, MI.

Abstract. TNG462 is a clinical-stage, MTA-cooperative PRMT5 inhibitor currently being evaluated in an ongoing phase I/II clinical trial for solid tumors with MTAP loss. Approximately 10-15% of all ...

Suzhou Genhouse Pharmaceutical Co., Ltd., Suzhou, China.

Celltrion Pharm, Inc., Incheon, Republic of Korea.

Cancer Research | 85 | 8_Supplement_1 | April 2025Journal Archive Cancer Research (1941-Present; volumes 1-current) Published twice monthly since 1987. From 1941-1986, published monthly. (ISSN ...

1Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.